Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Seetharaman Balasenthil Image

      Seetharaman Balasenthil, Ph.D.

      Department of Translational Molecular Pathology, Division of Pathology-Lab Medicine Div

      Present Title & Affiliation

      Primary Appointment

      Assistant Professor, Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

      Dual/Joint/Adjunct Appointment

      Assistant Professor, Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

      Education & Training

      Degree-Granting Education

      2001Annamalai University, Tamil Nadu, IN, Biochemistry, Ph.D
      1997Annamalai University, Tamil Nadu, IN, Biochemistry, MPhil
      1996Annamalai University, Tamil Nadu, IN, Biochemistry, M.S
      1994University of Madras, Tamil Nadu, IN, Biochemistry, BS

      Postgraduate Training

      2001-2006Research Fellowship, UTMDACC, Houston, Texas

      Experience & Service

      Faculty Academic Appointments

      Instructor, Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2017

      Instructor, Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2013

      Instructor, Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2006 - 2008

      Honors & Awards

      2021 - 2022Early Career Faculty, Division of Pathology and Laboratory Medicine
      20061st Place AMGEN Award in Basic Science Research, UTMDACC 10th Annual Trainee Recognition Day
      20041st Place AMGEN Award in Basic Science Research, UTMDACC 8th Annual Trainee Recognition Day
      2003Honorable Mention, UTMDACC 7th Annual Trainee Recognition Day
      2002Honorable Mention, UTMDACC 6th Annual Trainee Recognition Day
      2000Young Scientist Award, EMSI Silver Jubilee Conference
      1999 - 2001Senior Research Fellowship, Council of Scientific and Industrial Research
      19962nd Prize, Quiz Competition, XXII Annual Conference of Clinical Biochemists of India
      1994 - 1996Dr. Rathinasami Endowment Special Prize for Academic and Extracurricular Activities, Annamalai Universtiy, Tamil Nadu, India

      Professional Memberships

      American Gastroenterological Association

      2024 - Present

      American Association for Cancer Research

      2018 - Present

      American Association for the Advancement of Science

      2018 - Present

      American Pancreatic Association

      2018 - Present

      Selected Presentations & Talks

      Local Presentations

      1. 2015. Departmental Retreat Seminar Series. Conference. Departmental Retreat Seminar Series. Houston, TX, US.
      2. 2013. Pancreatic cancer. Conference. Pancreatic cancer. Houston, TX, US.
      3. 2006. First Place Platform Presentation. Conference. First Place Platform Presentation. Houston, TX, US.
      4. 2004. First Place Platform Presentation. Conference. First Place Platform Presentation. Houston, TX, US.

      Regional Presentations

      1. 2017. Optimization of Gene Editing Technology for Generation of DEAR1 Knockout in Human Breast Cancer Cells. Poster. Optimization of Gene Editing Technology for Generation of DEAR1 Knockout in Human Breast Cancer Cells. Austin, TX, US.
      2. 2017. The role of Ductal Epithelium Associated Ring Chromosome 1 (DEAR1) in the regulation of stem/progenitor cell properties. Poster. The role of Ductal Epithelium Associated Ring Chromosome 1 (DEAR1) in the regulation of stem/progenitor cell properties. Austin, TX, US.
      3. 2015. The tumor suppressor DEAR1 negatively regulates TGF beta-driven EMT in breast cancer. Poster. Austin, TX, US.

      National Presentations

      1. 2019. Migration Signature Biomarker Panel Improves Gold Standard CA19-9 Performance for Detection of Early Stage Pancreatic Cancer in the Blood. Conference. Migration Signature Biomarker Panel Improves Gold Standard CA19-9 Performance for Detection of Early Stage Pancreatic Cancer in the Blood. Maui, HI, US.
      2. 2019. On the Role of DEAR1 as a novel ubiquitin ligase for ER alpha and predictor of tamoxifen response in ER positive breast cancer. Conference. AACR 2019 Annual Meeting. Atlanta, GA, US.
      3. 2019. Low Expression of Tumor Suppressor DEAR1 in the Triple Negative Breast Cancer Correlated with Young Age and Early Metastasis. Poster. USCAP 108th Annual Meeting. National Harbor, MD, US.
      4. 2015. Validation Studies Using the EDRN Pancreatic Cancer Reference Set. Invited. 29 th Early Detection Research Network (EDRN) Steering Committee Meeting, Gastrointestinal & Associated Cancers Collaborative Group Meeting. Atlanta, GA, US.
      5. 2004. Modulation of hormonal responsiveness by the status and subcellular localization of ER and MTA family members. Conference. Modulation of hormonal responsiveness by the status and subcellular localization of ER and MTA family members. Orlando, FL, US.
      6. Novel role of the tumor suppressor ductal epithelium associated ring chromosome 1 (DEAR1) in regulation of breast stem/progenitor cell properties. Conference. Novel role of the tumor suppressor ductal epithelium associated ring chromosome 1 (DEAR1) in regulation of breast stem/progenitor cell properties. San Antonio, TX, US.
      7. HER2 regulation of PPARγ expression and sensitivity of breast cancer cells to PPARγ ligand therapy. Conference. Hormonal Carcinogenesis Gordon Research Conference. Meriden, US.
      Read More
      Less

      Grant & Contract Support

      Date: 2025 - Present
      Title:A novel protein-based blood test for the early detection of pancreatic cancer
      Funding Source:NIH-Seed GCC REACH
      Role:PI
      Date: 2024 - 2029
      Title:Circulating Biomarkers and Imaging for Early Detection of Pancreatic Cancer
      Funding Source:NIH/NCI
      Role:Co-I
      ID:2U01CA214263-06
      Date: 2024 - 2027
      Title:DEAR1 in the Regulation of Epithelial-Mesenchymal Plasticity and as a Predictive Biomarker to Stratify Triple Negative Breast Cancers for Precision Therapy
      Funding Source:DOD
      Role:Co-I
      ID:BC231160
      Date: 2024 - 2027
      Title:An Integromics Approach for the Identification of high-risk IPMNs
      Funding Source:AACR
      Role:Co-I
      ID:1259743
      Date: 2024 - 2026
      Title:Intergromic Approach for the Identification of Invasive IPMNs
      Funding Source:American Cancer Society
      Role:Co-I
      ID:DBG-1257713
      Date: 2024 - 2026
      Title:An Intergromic Approach for Identification of Invasive Intraductal Papillary Mucinous Neoplasms
      Funding Source:NIH/NCI
      Role:Co-PI
      ID:1R2CA273835-01A1
      Date: 2023 - 2026
      Title:DEAR1 as a critical regulator of epithelial-mesenchymal plasticity to stratify triple negative breast cancers for precision therapy in an organoid model
      Funding Source:DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
      Role:Co-I
      ID:BC221135
      Date: 2023 - 2026
      Title:An Intregromic Approach for the Identification of Invasive Intraductal Papillary Mucinous Neoplasms
      Funding Source:DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
      Role:Co-I
      ID:PA220201
      Date: 2023 - 2026
      Title:An Integromics Approach for the Identification of high-risk IPMNs
      Funding Source:AACR
      Role:Co-I
      ID:1040068
      Date: 2023 - 2026
      Title:DEAR1 as a Critical Regulator of Epithelial-Mesenchymal Plasticity to Stratify Triple-Negative Breast Cancers for Precision Therapy Using an Organoid Model
      Funding Source:CPRIT
      Role:Co-I
      ID:RP230255
      Date: 2022 - 2025
      Title:Preclinical Studies on DEAR1 as a Predictive Biomarker to Stratify Triple Negative Breast Cancers for Precision Therapy in an Organoid Model
      Funding Source:DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
      Role:Co-I
      ID:BC211082
      Date: 2022 - 2024
      Title:An Integromic Approach for Identification of Invasive Intraductal Papillary Mucinous Neoplasms
      Funding Source:NIH/NCI
      Role:Co-PI
      ID:1 R21 CA273835-01
      Date: 2022 - 2026
      Title:Blood-based biomarkers for the early detection of pancreatic cancer
      Funding Source:Cancer Prevention & Research Institute of Texas (CPRIT)
      Role:PI
      ID:RP220443
      Date: 2022 - 2025
      Title:Preclinical Studies on DEAR1 as a Predictive Biomarker to Stratify Triple Negative Breast Cancers for Precision Therapy in an Organoid Model
      Funding Source:Cancer Prevention & Research Institute of Texas (CPRIT)
      Role:Co-I
      ID:RP220113
      Date: 2021 - 2022
      Title:Novel Regulatory Role of DEAR1 in c-Myc-mediated Stemness in Triple Negative Breast Cancer
      Funding Source:Division of Pathology and Laboratoty Medicine
      Role:PI
      Date: 2021 - 2023
      Title:Novel Regulatory Role of DEAR1 in c-Myc-Mediated Stemness and Metastasis in Triple Negative Breast Cancer
      Funding Source:NIH/NCI
      Role:Co-PI
      ID:1 R21 CA235383-01A1
      Date: 2020 - 2021
      Title:DEAR1 Loss as a Predictive Marker in Endometrial Uterine Serous Carcinoma
      Funding Source:NIH/NCI
      Role:PI
      Date: 2020 - 2023
      Title:Novel regulatory role of DEAR1 in c-Myc-mediated stemness and metastasis in triple negative breast cancer
      Funding Source:Cancer Prevention & Research Institute of Texas (CPRIT)
      Role:Co-PI
      ID:FP00008414
      Date: 2018 - 2020
      Title:Novel regulatory role of DEAR1 in c-Myc-mediated stemness and metastasis in triple negative breast cancer
      Funding Source:NIH/NCI
      Role:Co-PI
      ID:1 R21 CA235383-01
      Date: 2018 - 2023
      Title:Circulating Biomarkers and Imaging for Early Detection of Pancreatic Cancer
      Funding Source:NIH/NCI
      Role:Co-I
      ID:NIH/NCI-PAR-15-289
      Date: 2018 - 2020
      Title:Novel regulatory role of DEAR1 in c-Myc-mediated stemness and metastasis in triple negative breast cancer
      Funding Source:Department of Defense (DOD)
      Role:Co-PI
      ID:BC171746
      Date: 2018 - 2023
      Title:Predictive Biomarkers of DCIS to Invasive Breast Cancer Progression
      Funding Source:NIH/NCI
      Role:Co-I
      ID:NIH/NCI-PA-16-160 R01
      Date: 2018 - 2021
      Title:Blood-based biomarkers for the early detection of pancreatic cancer
      Funding Source:Cancer Prevention & Research Institute of Texas (CPRIT)
      Role:Co-I
      ID:RP180607
      Date: 2015 - 2018
      Title:DEAR1 as a novel regulator of cell polarity and progression from DCIS to invasive breast cancer
      Funding Source:Cancer Prevention & Research Institute of Texas (CPRIT)
      Role:Co-I
      ID:RP150403
      Date: 2014 - 2016
      Title:Functional Genomic Biomarker Signatures for the Early Detection of Pancreatic Cancer
      Funding Source:Pancreatic Moon Shot Funding
      Role:Co-PI
      ID:710499-80-114637-21
      Date: 2014 - 2015
      Title:Chromosome 1p tumor suppressor DEAR1 as a novel E3 ligase for EGFR and a predictive marker for EGFR inhibitor resistance in non-small cell lung cancer
      Funding Source:Department of Defense (DOD)
      Role:PI
      ID:LC130939
      Date: 2014 - 2017
      Title:On the role of DEAR1 as a novel ubiquitin ligase for ER alpha and predictor of tamoxifen response in ER positive breast cancer
      Funding Source:Cancer Prevention & Research Institute of Texas (CPRIT)
      Role:Co-PI
      ID:RP140657
      Date: 2012 - 2015
      Title:DEAR1 Loss of Function Involved in Progression of DCIS to Invasive Breast Cancer
      Funding Source:Department of Defense (DOD)
      Role:Investigator
      ID:DAMD BC111524
      Date: 2010 - 2017
      Title:Biomarkers for the Early Detection of Pancreatic Cancer
      Funding Source:NIH/NCI
      Role:Co-I
      ID:2U01 CA111302-10
      Title:Regulation of Hypoxia Inducible Factor Alpha-Mediated Metastatic Niche by DEAR1
      Funding Source:Department of Defense (DOD)
      Role:PI
      ID:BC133327
      Title:Characterization of DEAR1 as a novel E3 Ubiquitin ligase for ER alpha and predictor of tamoxifen response in ER + Breast Cancer
      Funding Source:AVON Foundation
      Role:PI

      Selected Publications

      Peer-Reviewed Articles

      1. Yao T-H, Treekitkarnmongkol W, Putluri N, Sankaran D, Nguyen T, Balasenthil S, Hurd MW, Chen M, Brand RE, Lampe PD, Kamal AHM, Putluri V, Hu TY, Maitra A, Koay EJ, Killary AM, Sen S, Kundu S. Machine Learning-Based Multimodal Biomarkers Enable Accurate Diagnosis and Early Detection of Pancreatic Ductal Adenocarcinoma. Sci Rep 16(1):658, 2026. e-Pub 2026. PMID: 41495079.
      2. Treekitkarnmongkol W, Dai J, Liu S, Sankaran D, Nguyen T, Balasenthil S, Hurd MW, Chen M, Katayama H, Roy-Chowdhuri S, Calin GA, Brand RE, Lampe PD, Hu TY, Maitra A, Koay EJ, Killary AM, Sen S. Blood-Based microRNA Biomarker Signature of Early-Stage Pancreatic Ductal Adenocarcinoma With Lead-Time Trajectory in Prediagnostic Samples. Gastro Hep Adv 3(8):1098-1115, 2024. e-Pub 2024. PMID: 39529638.
      3. Balasenthil S, Liu S, Dai J, Bamlet WR, Petersen G, Chari ST, Maitra A, Chen N, Sen S, Killary AM. Blood-based Migration Signature Biomarker Panel Discriminates Early Stage New Onset Diabetes related Pancreatic Ductal Adenocarcinoma from Type 2 Diabetes. Clin Chim Acta 551:117567, 2023. e-Pub 2023. PMID: 37774897.
      4. Le, UQ, Chen, N, Balasenthil, S, Lurie, E, Yang, F, Liu, S, Rubin, L, Solis Soto, LM, Raso, G, Batra, H, Sahin, AA, Wistuba, II, Killary, AM. Tumor suppressor DEAR1 regulates mammary epithelial cell fate and predicts early onset and metastasis in triple negative breast cancer. Sci Rep 12(1), 2022. e-Pub 2022. PMID: 36376460.
      5. Balasenthil, S, Huang, Y, Liu, S, Marsh, T, Chen, J, Stass, SA, KuKuruga, D, Brand, RE, Chen, N, Frazier, ML, Lee, JJ, Srivastava, S, Sen, S, Killary, AM. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer. J Natl Cancer Inst 109(8), 2017. e-Pub 2017. PMID: 28376184.
      6. Haab, BB, Huang, Y, Balasenthil, S, Partyka, K, Tang, H, Anderson, MA, Allen, PJ, Sasson, AR, Zeh, H, Kaul, KL, Kletter, D, Ge, S, Bern, M, Kwon, R, Blasutig, I, Srivastava, S, Frazier, ML, Sen, S, Hollingsworth, MA, Rinaudo, JA, Killary, AM, Brand, RE. Definitive characterization of CA 19-9 in resectable pancreatic cancer using a reference set of serum and plasma specimens. PloS one 10(10), 2015. e-Pub 2015. PMID: 26431551.
      7. Chen, N, Balasenthil, S, Reuther, J, Frayna, A, Wang, Y, Chandler, DS, Abruzzo, L, Rashid, A, Rodriguez Canales, J, Lozano, G, Cao, Y, Lokken, E, Chen, J, Frazier, ML, Sahin, AA, Wistuba, II, Sen, S, Lott, ST, Killary, AM. Dear1 is a chromosome 1p35 tumor suppressor and master regulator of TGF-β-driven epithelial-mesenchymal transition. Cancer Discov 3(10):1172-1189, 2013. e-Pub 2013. PMID: 23838884.
      8. Li, DQ, Pakala, SB, Reddy, SN, Peng, S, Balasenthil, S, Deng, CX, Lee, CC, Rea, MA, Kumar, R. Metastasis-associated protein 1 is an integral component of the circadian molecular machinery. Nat Commun 4, 2013. e-Pub 2013. PMID: 24089055.
      9. Balasenthil, S, Chen, N, Lott, ST, Chen, J, Carter, J, Grizzle, WE, Frazier, ML, Sen, S, Killary, AM. A migration signature and plasma biomarker panel for pancreatic adenocarcinoma. Cancer Prev Res (Phila) 4(1):137-149, 2011. e-Pub 2011. PMID: 21071578.
      10. Kumar, R, Balasenthil, S, Manavathi, B, Rayala, SK, Pakala, SB. Metastasis-associated protein 1 and its short form variant stimulates Wnt1 transcription through promoting its derepression from Six3 corepressor. Cancer Res 70(16):6649-6658, 2010. e-Pub 2010. PMID: 20682799.
      11. Kumar, R, Balasenthil, S, Pakala, SB, Rayala, SK, Sahin, AA, Ohshiro, K. Metastasis-associated protein 1 short form stimulates Wnt1 pathway in mammary epithelial and cancer cells. Cancer Res 70(16):6598-6608, 2010. e-Pub 2010. PMID: 20710043.
      12. Lott, ST, Chen, N, Chandler, DS, Yang, Q, Wang, L, Rodriguez, M, Xie, H, Balasenthil, S, Buchholz, TA, Sahin, AA, Chaung, K, Zhang, B, Olufemi, SE, Chen, J, Adams, H, Band, V, El-Naggar, AK, Frazier, ML, Keyomarsi, K, Hunt, KK, Sen, S, Haffty, BG, Hewitt, SM, Krahe, R, Killary, AM. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med 6(5), 2009. e-Pub 2009. PMID: 19536326.
      13. Chakravarty, D, Nair, SS, Rajhans, R, Pitcheswara, PR, Liu, J, Balasenthil, S, Le, X, Burow, ME, Auersperg, N, Tekmal, RR, Broaddus, R, Vadlamudi, RK. Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res 68(12):4902-4909, 2008. e-Pub 2008. PMID: 18559538.
      14. Manavathi, B, Peng, S, Rayala, SK, Talukder, AH, Wang, MH, Wang, RA, Balasenthil, S, Agarwal, N, Frishman, LJ, Kumar, R. Repression of Six3 by a corepressor regulates rhodopsin expression. Proc Natl Acad Sci U S A 104(32):13128-13133, 2007. e-Pub 2007. PMID: 17666527.
      15. Balasenthil, S, Gururaj, AE, Talukder, AH, Yarmand, R, Arrington, T, Haas, BJ, Braisted, JC, Kim, I, Lee, NH, Kumar, R. Identification of Pax5 as a target of MTA1 in B-cell lymphomas. Cancer Res 67(15):7132-7138, 2007. e-Pub 2007. PMID: 17671180.
      16. Yarmand, R, Balasenthil, S, Gururaj, AE, Talukder, AH, Wang, YH, Ju, HL, Young, SK, Zhang, X, Jones, D, Medeiros, LJ, Stephens, C, Liu, YJ, Lee, NH, Kim, I, Kumar, R. Metastasis-associated protein 1 transgenic mice:A new model of spontaneous B-cell lymphomas. Cancer Res 67(15):7062-7067, 2007. e-Pub 2007. PMID: 17671172.
      17. Singh, RR, Kaluarachchi, K, Chen, M, Rayala, SK, Balasenthil, S, Ma, J, Kumar, R. Solution structure and antiestrogenic activity of the unique C-terminal, NR-box motif-containing region of MTA1s. J Biol Chem 281(35):25612-25621, 2006. e-Pub 2006. PMID: 16807247.
      18. Balasenthil, S, Broaddus, R, Kumar, R. Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. Human Pathol 37(6):656-661, 2006. e-Pub 2006. PMID: 16733204.
      19. Wang, RA, Zhang, H, Balasenthil, S, Medina, D, Kumar, R. PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene 25(20):2931-2936, 2006. e-Pub 2006. PMID: 16331248.
      20. Gururaj, AE, Singh, RR, Rayala, SK, Holm, C, Den Hollander, P, Zhang, H, Balasenthil, S, Talukder, AH, Landberg, G, Kumar, R. MTA1, a transcriptional activator of breast cancer amplified sequence 3. Proc Natl Acad Sci U S A 103(17):6670-6675, 2006. e-Pub 2006. PMID: 16617102.
      21. Rayala, SK, Den Hollander, P, Balasenthil, S, Molli, PR, Bean, AJ, Vadlamudi, RK, Wang, RA, Kumar, R. Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) interacts with PELP1 and activates MAPK. J Biol Chem 281(7):4395-4403, 2006. e-Pub 2006. PMID: 16352611.
      22. Rayala, SK, Talukder, AH, Balasenthil, S, Tharakan, R, Barnes, CJ, Wang, RA, Aldaz, CM, Khan, S, Kumar, R. P21-activated kinase 1 regulation of estrogen receptor-α activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res 66(3):1694-1701, 2006. e-Pub 2006. PMID: 16452229.
      23. Vadlamudi, RK, Manavathi, B, Balasenthil, S, Nair, SS, Yang, Z, Sahin, AA, Kumar, R. Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Res 65(17):7724-7732, 2005. e-Pub 2005. PMID: 16140940.
      24. Rayala, SK, Den Hollander, P, Balasenthil, S, Yang, Z, Broaddus, R, Kumar, R. Functional regulation of oestrogen receptor pathway by the dynein light chain 1. EMBO Rep 6(6):538-544, 2005. e-Pub 2005. PMID: 15891768.
      25. Vadlamudi, RK, Balasenthil, S, Sahin, AA, Kies, MS, Weber, RS, Kumar, R, El-Naggar, AK. Novel estrogen receptor coactivator PELP1/MNAR gene and ERβ expression in salivary duct adenocarcinoma. Human Pathol 36(6):670-675, 2005. e-Pub 2005. PMID: 16021574.
      26. Vadlamudi, RK, Barnes, CJ, Rayala, SK, Li, F, Balasenthil, S, Marcus, S, Goodson, HV, Sahin, AA, Kumar, R. p21-activated kinase 1 regulates microtubule dynamics by phosphorylating tubulin cofactor B. Mol Cell Biol 25(9):3726-3736, 2005. e-Pub 2005. PMID: 15831477.
      27. Vadlamudi, RK, Balasenthil, S, Broaddus, R, Gustafsson, JA, Kumar, R. Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. J Clin Endocrinol Metab 89(12):6130-6138, 2004. e-Pub 2004. PMID: 15579769.
      28. Nair, SS, Mishra, SK, Yang, Z, Balasenthil, S, Kumar, R, Vadlamudi, RK. Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res 64(18):6416-6423, 2004. e-Pub 2004. PMID: 15374949.
      29. Balasenthil, S, Barnes, CJ, Rayala, SK, Kumar, R. Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells. FEBS Letters 567(2-3):243-247, 2004. e-Pub 2004. PMID: 15178330.
      30. Vadlamudi, RK, Yarmand, R, Yang, Z, Balasenthil, S, Nguyen, D, Sahin, AA, Den Hollander, P, Kumar, R. Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer cell 5(6):575-585, 2004. e-Pub 2004. PMID: 15193260.
      31. Mishra, SK, Balasenthil, S, Nguyen, D, Vadlamudi, RK. Cloning and functional characterization of PELP1/MNAR promoter. Gene 330(1-2):115-122, 2004. e-Pub 2004. PMID: 15087130.
      32. Balasenthil, S, Sahin, AA, Barnes, CJ, Wang, RA, Pestell, RG, Vadlamudi, RK, Kumar, R. p21-activated Kinase-1 Signaling Mediates Cyclin D1 Expression in Mammary Epithelial and Cancer Cells. J Biol Chem 279(2):1422-1428, 2004. e-Pub 2004. PMID: 14530270.
      33. Yang, Z, Yarmand, R, Balasenthil, S, Hortobagyi, GN, Sahin, AA, Barnes, CJ, Kumar, R. HER2 regulation of peroxisome proliferator-activated receptor γ (PPARγ) expression and sensitivity of breast cancer cells to PPARγ ligand therapy. Clinical Cancer Res 9(8):3198-3203, 2003. e-Pub 2003. PMID: 12912973.
      34. Balasenthil, S, Vadlamudi, RK. Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. J Biol Chem 278(24):22119-22127, 2003. e-Pub 2003. PMID: 12682072.
      35. Talukder, AH, Mishra, SK, Mandal, M, Balasenthil, S, Mehta, S, Sahin, AA, Barnes, CJ, Kumar, R. MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates estrogen receptor transactivation functions. J Biol Chem 278(13):11676-11685, 2003. e-Pub 2003. PMID: 12527756.
      36. Balasenthil, S, Rao, KS, Nagini, S. Altered cytokeratin expression during chemoprevention of hamster buccal pouch carcinogenesis by S-allylcysteine. Pol J Pharmacol 55(5):793-798, 2003. e-Pub 2003. PMID: 14704476.
      37. Balasenthil, S, Rao, KS, Nagini, S. Retinoic acid receptor-β mRNA expression during chemoprevention of hamster cheek pouch carcinogenesis by garlic. Asia Pac J Clin Nutr 12(2):215-218, 2003. e-Pub 2003. PMID: 12810414.
      38. Balasenthil, S, Nagini, S. Protective effects of S-allylcysteine on hepatic glutathione and glutathione-dependent enzymes during hamster cheek pouch carcinogenesis. J Biochem Mol Biol Biophys 6(1):13-16, 2002. e-Pub 2002. PMID: 12186777.
      39. Balasenthil, S, Rao, KS, Nagini, S. Garlic induces apoptosis during 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. Oral Oncol 38(5):431-436, 2002. e-Pub 2002. PMID: 12110336.
      40. Balasenthil, S, Rao, KS, Nagini, S. Altered cytokeratin expression during chemoprevention of experimental hamster buccal pouch carcinogenesis by garlic. J Oral Pathol Med 31(3):142-146, 2002. e-Pub 2002. PMID: 11903819.
      41. Balasenthil, S, Rao, KS, Nagini, S. Apoptosis induction by S-allylcysteine, a garlic constituent, during 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. Cell Biochem Funct 20(3):263-268, 2002. e-Pub 2002. PMID: 12125104.
      42. Velmurugan, B, Bhuvaneswari, V, Balasenthil, S, Nagini, S. Lycopene, an antioxidant carotenoid modulates glutathione-dependent hepatic biotransformation enzymes during experimental gastric carcinogenesis. Nutr Res 21(8):1117-1124, 2001. e-Pub 2001.
      43. Saroja, M, Balasenthil, S, Ramachandran, CR, Nagini, S. Coffee enhances the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster buccal pouch carcinomas. Oral Oncol 37(2):172-176, 2001. e-Pub 2001. PMID: 11167145.
      44. Arivazhagan, S, Balasenthil, S, Nagini, S. Attenuation by garlic and neem leaf extracts of sodium chloride - Enhanced gastric carcinogenesis induced by N-methyl-N′-Nitro-N-Nitrosoguanidine (MNNG) in Wistar rats. GI Cancer 3(5):375-382, 2001. e-Pub 2001.
      45. Bhuvaneswari, V, Velmurugan, B, Balasenthil, S, Ramachandran, CR, Nagini, S. Chemopreventive efficacy of lycopene on 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. Fitoterapia 72(8):865-874, 2001. e-Pub 2001. PMID: 11731111.
      46. Balasenthil, S, Ramachandran, CR, Nagini, S. S-allylcysteine, a garlic constituent, inhibits 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. Nutr Cancer 40(2):165-172, 2001. e-Pub 2001. PMID: 11962252.
      47. Balasenthil, S, Ramachandran, CR, Nagini, S. Garlic inhibits experimentally induced hamster buccal pouch carcinomas. J Biochem Mol Biol Biophys 5(4):261-266, 2001. e-Pub 2001.
      48. Balasenthil, S, Ramachandran, CR, Nagini, S. Prevention of 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis by garlic. Fitoterapia 72(5):524-531, 2001. e-Pub 2001. PMID: 11429247.
      49. Balasenthil, S, Arivazhagan, S, Nagini, S. Garlic enhances circulatory antioxidants during 7,12- dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. J Ethnopharmacol 72(3):429-433, 2000. e-Pub 2000. PMID: 10996282.
      50. Balasenthil, S, Nagini, S. Inhibition of 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis by S-allylcysteine. Oral Oncol 36(4):382-386, 2000. e-Pub 2000. PMID: 10899678.
      51. Arivazhagan, S, Balasenthil, S, Nagini, S. Garlic and neem leaf extracts enhance hepatic glutathione and glutathione dependent enzymes during N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced gastric carcinogenesis in rats. Phytother Res 14(4):291-293, 2000. e-Pub 2000. PMID: 10861977.
      52. Balasenthil, S, Saroja, M, Ramachandran, CR, Nagini, S. Of humans and hamsters: Comparative analysis of lipid peroxidation, glutathione, and glutathione-dependent enzymes during oral carcinogenesis. Br J Oral Maxillofac Surg 38(4):267-270, 2000. e-Pub 2000. PMID: 10922148.
      53. Balasenthil, S, Sahoo, GC, Nagini, S. Circulatory lipid peroxidation and antioxidants in pharyngeal cancer patients. J Biochem Mol Biol Biophys 4(5):359-362, 2000. e-Pub 2000.
      54. Balasenthil, S, Nagini, S. Enhancement of circulatory antioxidants by S-allylcysteine during 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. J Biochem Mol Biol Biophys 4(1):35-39, 2000. e-Pub 2000.
      55. Balasenthil, S, Arivazhagan, S, Nagini, S. Effect of garlic on circulatory oxidant and antioxidant status during 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis. Nutr Res 20(11):1581-1589, 2000. e-Pub 2000.
      56. Arivazhagan S, Balasenthil S, Nagini S. Modulatory effects of garlic and neem leaf extracts on N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced oxidative stress in Wistar rats. Cell Biochem Funct 18(1):17-21, 2000. e-Pub 2000. PMID: 10686579.
      57. Balasenthil S, Nagini S. Garlic exerts hepatoprotective effects during 4-nitroquinoline 1-oxide-induced oral carcinogenesis in rats. Asia Pac J Clin Nutr 9(2):136-138, 2000. e-Pub 2000. PMID: 24394400.
      58. Balasenthil, S, Arivazhagan, S, Nagini, S. Chemoprotective effects of neem leaf extract on 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster buccal pouch carcinogenesis. J Clin Biochem Funct 26(1):9-15, 1999. e-Pub 1999.
      59. Arivazhagan, S, Balasenthil, S, Nagini, S. Modulatory effects of garlic and neem leaf extracts on circulatory lipid peroxides and antioxidants during N-methyl-N’ -nitro-N-nitrosoguanidine-induced gastric carcinogenesis. Med Sci Res 27(8):527-529, 1999. e-Pub 1999.
      60. Balasenthil S, Arivazhagan S, Ramachandran CR, Ramachandran V, Nagini S. Chemopreventive potential of neem (Azadirachta indica) on 7,12-dimethylbenz- [a]anthracene (DMBA) induced hamster buccal pouch carcinogenesis. J Ethnopharmacol 67(2):189-95, 1999. e-Pub 1999. PMID: 10619383.
      61. Arivazhagan, S, Balasenthil, S, Nagini, S. Chemopreventive potential of garlic and neem during N-methyl-N’-nitro-N-nitrosoguanidine-induced gastric carcinogenesis. Med Sci Res 27:209-212, 1999. e-Pub 1999.
      62. Balasenthil S, Arivazhagan S, Ramachandran CR, Nagini S. Effects of garlic on 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. Cancer Detect Prev 23(6):534-8, 1999. e-Pub 1999. PMID: 10571664.
      63. Saroja M, Balasenthil S, Nagini S. Tissue lipid peroxidation and glutathione-dependent enzyme status in patients with oral squamous cell carcinoma. Cell Biochem Funct 17(3):213-216, 1999. e-Pub 1999. PMID: 10451543.
      64. Balasenthil, S, Nagini, S. Hepatoprotective effects of garlic during hamster buccal pouch carcinogenesis induced by 7,12-dimethylbenz[a]anthracene. Med Sci Res 26(12):849-851, 1998. e-Pub 1998.
      65. Oberg A, Bamlet W, Izmirlian G, Balasenthil S, Batra S, Hayashi M, Herman D, Hollingsworth M, Jain M, Killary A, Krusen B, Liu S, Majumder S, Natarajan G, Sen S, Smith L, Srivastava S, Wolpin B, Zaret K, Goggins M. Pancreatic Cancer Detection Consortium Biomarker Bake-Off: A Phase 2 blinded biomarker validation and panel discovery study. Clin Cancer Res.

      Review Articles

      1. Chen, N, Balasenthil, S, Reuther, J, Killary, AM. DEAR1, a novel tumor suppressor that regulates cell polarity and epithelial plasticity. Cancer Res 74(20):5683-5689, 2014. e-Pub 2014. PMID: 25261235.

      Other Articles

      1. Vadlamudi, RK, Yarmand, R, Yang, Z, Balasenthil, S, Nguyen, D, Sahin, AA, Den Hollander, P Overexpressed DLC1 as target for breast cancer cell shape and survival. Cancer Biology and Therapy 3(7):587-588, 2004. PMID: 15754445.

      Abstracts

      1. Balasenthil S, Bamlet WR, Izmirlian G, Balasenthil S, Batra SK, Hayashi M, Herman D, Hollingsworth MA, Jain M, Killary AM, Krusen BM, Liu S, Natarajan G, Sen S, Smith LM, Srivastava S, Wolpin BM, Zaret KS, Goggins MG. Pancreatic Cancer Detection Consortium biomarker bake-off: A consortium Phase 2 blinded biomarker validation and panel discovery study. AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions 85(18), 2025. e-Pub 2025.
      2. Balasenthil S, Huang Y, Liu S, Marsh T, Chen J, Stass SA, KuKuruga D, Brand R, Chen N, Frazier ML, Lee JJ, Srivastava S, Sen S, Killary AM. Migration Signature Biomarker Panel Improves Gold Standard CA19-9 Performance for Detection of Early Stage Pancreatic Cancer in the Blood. 50th Anniversary Meeting: American Pancreatic Association, Japan Pancreas Society, 2019. e-Pub 2019.
      3. Yang F, Le U, Chen N, Balasenthil S, Mino B, Liu S, Rubin M, Sahin A, Wistuba I, Killary A. Low Expression of Tumor Suppressor DEAR1 in the Triple Negative Breast Cancer Correlated with Young Age and Early Metastasis. USCAP 108th Annual Meeting 32(Supplement 2):164, 2019. e-Pub 2019.
      4. Balasenthil S, Chen N, Killary A. On the role of DEAR1 as a novel ubiquitin ligase for ER alpha and predictor of tamoxifen response in ER positive breast cancer 79(13_Supplement), 2019. e-Pub 2019.
      5. Le U, Chen N, Balasenthil S, Killary AM. Novel role of the tumor suppressor ductal epithelium associated ring chromosome 1 (DEAR1) in regulation of breast stem/progenitor cell properties. San Antonio Breast Cancer Symposium 79(4_Supplement):P1-07-01, 2018. e-Pub 2018.
      6. Le U, Chen N, Balasenthil S, Killary AM. The role of DEAR1 in the regulation of epithelial-mesenchymal transition and acquisition of stem cell properties. Mammary gland biology, Gordon Research Conference, Jun 11-16, 2017, Stowe, VT, 2017. e-Pub 2017.
      7. Chen N, Balasenthil S, Le U, Killary AM. The Tumor Suppressor DEAR1 Regulates Polarity and EMT in Human Mammary Epithelial Cells. Mammary gland biology, Gordon Research Seminar, Renaissance Tuscany Il Ciocco Resort Lucca (Barga), Italy, May 29-Jun 3, 2016, 2016. e-Pub 2016.
      8. Balasenthil S, Killary AM. Validation Studies Using the EDRN Pancreatic Cancer Reference Set. 29th Early Detection Research Network (EDRN) Steering Committee Meeting, Gastrointestinal & Associated Cancers Collaborative Group Meeting, 2015. e-Pub 2015.
      9. Chen N, Balasenthil S, Killary AM. The tumor suppressor DEAR1 negatively regulates TGF beta-driven EMT in breast cancer. IV Innovations in Cancer Prevention and Research Conference, Cancer Prevention& Research Institute of Texas, November 9-10 2015, Austin, TX:89, 2015. e-Pub 2015.
      10. Wang J, Balasenthil S, Huang Y-J, Chen J, Reuther J, Chen N, Brand R, Frazier ML, Killary AM, Sen S. A genomic pathway approach to biomarker discovery for the early detection and risk assessment of pancreatic cancer. 9th EDRN Scientific Workshop, 2014. e-Pub 2014.
      11. Chen N, Balasenthil S, Cao Y, Killary AM. DEAR1 orchestrates selective control over the epithelial-mesenchymal transition axis of TGFβ's function. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Invasion and Metastasis; Jan 20-23, 2013; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2013;73(3 Suppl):Abstract nr C71, 2013. e-Pub 2013.
      12. Balasenthil S, Wang J, Huang Y-J, Chen J, Reuther J, Chen N, Brand R, Stass S, Frazier ML, Killary AM, Sen S. A functional genomic approach to biomarker discovery in pancreatic cancer. 8th EDRN Scientific Workshop, 2013. e-Pub 2013.
      13. Chen N, Balasenthil S, Cao Y, Killary AM. DEAR1 orchestrates selective control over the epithelial-mesenchymal transition axis of TGFβ's function. AACR Special Conference on Tumor Invasion and Metastasis 73(3_Supplement), 2013. e-Pub 2013.
      14. Reuther J, Chen N, Balasenthil S, Killary A. Discovery and Functional Characterization of Somatic Mutations in the Novel Tumor Suppressor DEAR1. Annual Meeting of American Society of Human Genetics, 2012. e-Pub 2012.
      15. Reuther J, Chen N, Balasenthil S, Killary A. The role of novel tumor suppressor DEAR1 in the regulation of apoptosis in breast cancer. Mammary Gland Biology, Gordon Research Seminar, 2012. e-Pub 2012.
      16. Chakravarty D, Nair S, Balasenthil S. PELP1/MNAR in ovarian cancer: implications in tumorigenesis. 98th AACR Annual Meeting 67(9_Supplement):4345, 2007. e-Pub 2007.
      17. Nair SS, Balasenthil S, Mueller JM, Koochekpour S, Schüle R, Kumar R, and Vadlamudi RK. PELP1/MNAR modulates LIM-only coactivator FHL2 transactivation functions. AACR 96th Annual Meeting, Anaheim, California 1279, 2005. e-Pub 2005.
      18. Wang RA, Balasenthil S, Kumar R. Ectopic overexpression of kinase active p21-activated kinase is sufficient to induce tumorigenesis in the mouse mammary gland. 96th AACR Annual Meeting 65(9_Supplement):249, 2005. e-Pub 2005.
      19. Nair SS, Balasenthil S, Mueller JM, Koochekpour S, Schule R, Kumar R, Vadlamudi RK. PELP1/MNAR modulates LIM-only coactivator FHL2 transactivation functions. 96th AACR Annual Meeting 65(9_Supplement), 2005. e-Pub 2005.
      20. Vadlamudi RK, Manavathi B, Balasenthil S, Yang Z, Sahin AA, Kumar R. Altered localization of ER-coregulator PELP1 promotes estrogen hypersensitivity and tamoxifen resistance. Era of Hope, DOD Breast Cancer Meeting, 2005. e-Pub 2005.
      21. Balasenthil S, Gururaj AE, Yang Z, Broaddus R, Vadlamudi RK, Kumar R. Modulation of hormonal responsiveness by the status and subcellular localization of ER and MTA family members. AACR 95th Annual Meeting 64(7_Supplement), 2004. e-Pub 2004.
      22. Vadlamudi RK, Balasenthil S, Kies M, Kumar R, El-Naggar AK. PELP1/MNAR co-activator and the hormonal receptor expression in salivary duct adenocarcinoma. 6th International Conference on Head and Neck Cancer, 2004. e-Pub 2004.
      23. Mishra S, Balasenthil S, Yang Z, Vadlamudi RK. PELP1/MNAR modulate ER genomic functions via histone H1 interactions. 95th AACR Annual Meeting 64(7_Supplement), 2004. e-Pub 2004.
      24. Kumar R, Vadlamudi RK, Barnes CJ, Balasenthil S. Signaling dependent phosphorylation of tubulin folding factor controls microtubule biogenesis and functions: a new potential target in cancer cells. 16th EORTC-NCI-AACR Symposium. Molecular Targets and cancer therapeutics, 2004. e-Pub 2004.
      25. Balasenthil S, Broaddus R, Kumar R, Gustafsson J-A, Vadmaludi RK. Potential Involvement of PELP1/MNAR in tamoxifen resistance. 26th Annual San Antonio Breast Cancer Symposium, 2003. e-Pub 2003.
      26. Balasenthil S, Vadlamudi RK. Regulatory and functional interactions between steroidal coactivator PELP1 and retinoblastoma protein. The Cell Cycle Cold Spring Harbor Laboratory Meeting, 2002. e-Pub 2002.
      27. Balasenthil S, Nagini S. 26th Annual Conference of Environmental Mutagen Society of India and International Symposium on Environmental Health Sciences in the 21st Century, 2001. e-Pub 2001.
      28. Balasenthil S, Nagini S. 25th Annual Meeting of Environmental Mutagen Society of India (EMSI), 2000. e-Pub 2000.
      29. Nagini S, Balasenthil S, Rao KS. S-allylcysteine induces apoptosis during 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. 5th International Symposium on Biotechnology in Preventive Oncology: Impact of Cancer Biotechnology on Diagnostic and Prognostic Indicators in Predictive Oncology and Therapy; Geneva, Switzerland; October 28-31, 2000, 2000. e-Pub 2000.
      30. Nagini S, Balasenthil S, Rao KS. S-allylcysteine induces apoptosis during 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. Impact of Cancer Biotechnology on Diagnostic and Prognostic Indicators in Predictive Oncology and Therapy. 5th International Symposium on Biotechnology in Preventive Oncology:, 2000. e-Pub 2000.
      31. Balasenthil S, Nagini S. 15th Asia Pacific Cancer Conference, 1999. e-Pub 1999.
      32. Balasenthil S, Arivazhagan S, Nagini S. Indo-Japanese Symposium on Frontiers in Electron Microscopy in the 21st Century and XXII Annual Meeting of Electron Microscopy Society of India, 1998. e-Pub 1998.

      Book Chapters

      1. Balasenthil S, Kumar R. Molecular mechanisms of the metastasis- associated gene family of coregulators: role in cancer and invasion. In: DNA Methylation,Epigenetics and Metastasis. Springer, 215-230.

      Patents

      1. Vadlamudi RK, Kumar R, Balasenthi S. Estrogen Receptor Modulators and Uses Thereof. Patent Number: 10/927,644.
      2. Killary AM, Lott ST, Chen N, Balasenthil S. ASSAY FOR DETECTION OF EARLY STAGE PANCREATIC CANCER. Patent Number: 7162398.
      3. Killary AM, Lott S, Chen N, Balasenthil S. ASSAY FOR DETECTION OF EARLY STAGE PANCREATIC CANCER. Patent Number: 11,693,007.
      4. Balasenthil S. ASSAY FOR DETECTION OF EARLY STAGE PANCREATIC CANCER. Patent Number: ZL201880027192.1.
      5. Killary AM, Lott S, Chen N, Balasenthil S. ASSAY FOR DETECTION OF EARLY STAGE PANCREATIC CANCER. Patent Number: EP3586136B1.
      Read More
      Less

      Patient Reviews


      CV information above last modified July 22, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top